Literature DB >> 25869097

Chronic myelomonocytic leukemia: Forefront of the field in 2015.

Christopher B Benton1, Aziz Nazha2, Naveen Pemmaraju3, Guillermo Garcia-Manero4.   

Abstract

Chronic myelomonocytic leukemia (CMML) includes components of both myelodysplastic syndrome and myeloproliferative neoplasms and is associated with a characteristic peripheral monocytosis. CMML is caused by the proliferation of an abnormal hematopoietic stem cell clone and may be influenced by microenvironmental changes. The disease is rare and has undergone revisions in its classification. We review the recent classification strategies as well as diagnostic criteria, focusing on CMML's genetic alterations and unique pathophysiology. We also discuss the latest molecular characterization of the disease, including how molecular factors affect current prognostic models. Finally, we focus on available treatment strategies, with a special emphasis on experimental and forthcoming therapies.
Copyright © 2015. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Chronic myelomonocytic leukemia; Myelodysplastic syndrome; Myeloproliferative neoplasms

Mesh：

Year:  2015        PMID： 25869097      PMCID： PMC4859155          DOI： 10.1016/j.critrevonc.2015.03.002

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN： 1040-8428            Impact factor:   6.312


  171 in total

1.  Hyperleukocytosis complicating lonafarnib treatment in patients with chronic myelomonocytic leukemia.

Authors:  A Buresh; J Perentesis; L Rimsza; S Kurtin; R Heaton; M Sugrue; A List
Journal:  Leukemia       Date:  2005-02       Impact factor: 11.528

2.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

3.  Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia.

Authors:  Daniela Cilloni; Sonia Carturan; Enrico Bracco; Valentina Campia; Valentina Rosso; Davide Torti; Chiara Calabrese; Valentina Gaidano; Pimjai Niparuck; Alessandra Favole; Elisabetta Signorino; Ilaria Iacobucci; Annalisa Morano; Luciana De Luca; Pellegrino Musto; Francesco Frassoni; Giuseppe Saglio
Journal:  Leuk Res       Date:  2013-02-12       Impact factor: 3.156

4.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

5.  Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes.

Authors:  M M Patnaik; E Padron; R R LaBorde; T L Lasho; C M Finke; C A Hanson; J M Hodnefield; R A Knudson; R P Ketterling; A Al-kali; A Pardanani; N A Ali; R S Komrokji; R S Komroji; A Tefferi
Journal:  Leukemia       Date:  2013-03-27       Impact factor: 11.528

6.  Clonal architecture of chronic myelomonocytic leukemias.

Authors:  Raphaël Itzykson; Olivier Kosmider; Aline Renneville; Margot Morabito; Claude Preudhomme; Céline Berthon; Lionel Adès; Pierre Fenaux; Uwe Platzbecker; Olivier Gagey; Philippe Rameau; Guillaume Meurice; Cédric Oréar; François Delhommeau; Olivier A Bernard; Michaela Fontenay; William Vainchenker; Nathalie Droin; Eric Solary
Journal:  Blood       Date:  2013-01-14       Impact factor: 22.113

7.  Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia.

Authors:  Esperanza Such; Ulrich Germing; Luca Malcovati; José Cervera; Andrea Kuendgen; Matteo G Della Porta; Benet Nomdedeu; Leonor Arenillas; Elisa Luño; Blanca Xicoy; Mari L Amigo; David Valcarcel; Kathrin Nachtkamp; Ilaria Ambaglio; Barbara Hildebrandt; Ignacio Lorenzo; Mario Cazzola; Guillermo Sanz
Journal:  Blood       Date:  2013-01-31       Impact factor: 22.113

8.  Prognostic score including gene mutations in chronic myelomonocytic leukemia.

Authors:  Raphaël Itzykson; Olivier Kosmider; Aline Renneville; Véronique Gelsi-Boyer; Manja Meggendorfer; Margot Morabito; Céline Berthon; Lionel Adès; Pierre Fenaux; Odile Beyne-Rauzy; Norbert Vey; Thorsten Braun; Torsten Haferlach; François Dreyfus; Nicholas C P Cross; Claude Preudhomme; Olivier A Bernard; Michaela Fontenay; William Vainchenker; Susanne Schnittger; Daniel Birnbaum; Nathalie Droin; Eric Solary
Journal:  J Clin Oncol       Date:  2013-05-20       Impact factor: 44.544

9.  Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.

Authors:  Benjamin S Braun; David A Tuveson; Namie Kong; Doan T Le; Scott C Kogan; Jacob Rozmus; Michelle M Le Beau; Tyler E Jacks; Kevin M Shannon
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-29       Impact factor: 11.205

10.  GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia.

Authors:  Eric Padron; Jeffrey S Painter; Sateesh Kunigal; Adam W Mailloux; Kathy McGraw; Jessica M McDaniel; Eunhee Kim; Christopher Bebbington; Mark Baer; Geoffrey Yarranton; Jeffrey Lancet; Rami S Komrokji; Omar Abdel-Wahab; Alan F List; Pearlie K Epling-Burnette
Journal:  Blood       Date:  2013-04-30       Impact factor: 25.476
View more
  7 in total

1.  Routine blood examinations combined with morphological analysis for the diagnosis of myelodysplastic/myeloproliferative neoplasms.

Authors:  Huanling Wu; Hui Sun; Zhifen Zhang; Xiangli Li; Yuantang Li; Li Li; Rui Xu; Zie Wang; Wenjun Tian
Journal:  Oncol Lett       Date:  2016-09-21       Impact factor: 2.967

2.  Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report.

Authors:  Huan Liu; Juan Cheng; Long Zhao; Qian Xu; Mingming Xue; Shuling Zhang; Bei Liu
Journal:  Oncol Lett       Date:  2018-03-12       Impact factor: 2.967

3.  Alteration in the Cytokine Secretion of Bone Marrow Stromal Cells from Patients with Chronic Myelomonocytic Leukemia Contribute to Impaired Hematopoietic Supportive Activity.

Authors:  Hui Shi; Yingshao Wang; Rong Li; Wen Xing; Feng-Chun Yang; Jie Bai; Yuan Zhou
Journal:  Stem Cells Int       Date:  2018-07-10       Impact factor: 5.443

Review 4.  Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions.

Authors:  Peter Valent; Attilio Orazi; Michael R Savona; Mrinal M Patnaik; Francesco Onida; Arjan A van de Loosdrecht; Detlef Haase; Torsten Haferlach; Chiara Elena; Lisa Pleyer; Wolfgang Kern; Tea Pemovska; Gregory I Vladimer; Julie Schanz; Alexandra Keller; Michael Lübbert; Thomas Lion; Karl Sotlar; Andreas Reiter; Theo De Witte; Michael Pfeilstöcker; Klaus Geissler; Eric Padron; Michael Deininger; Alberto Orfao; Hans-Peter Horny; Peter L Greenberg; Daniel A Arber; Luca Malcovati; John M Bennett
Journal:  Haematologica       Date:  2019-05-02       Impact factor: 9.941

5.  Kidney Involvement in Patients With Chronic Myelomonocytic Leukemia or BCR-ABL-Negative Myeloproliferative Neoplasms.

Authors:  Julie Belliere; Magali Colombat; Clément Kounde; Christian Recher; David Ribes; Antoine Huart; Dominique Chauveau; Véronique Demas; Isabelle Luquet; Odile Beyne-Rauzy; Suzanne Tavitian; Stanislas Faguer
Journal:  Kidney Int Rep       Date:  2020-12-14

Review 6.  Transformation of Canine Lymphoma/Leukemia to More Aggressive Diseases: Anecdotes or Reality?

Authors:  Stefano Comazzi; Luca Aresu; Laura Marconato
Journal:  Front Vet Sci       Date:  2015-10-07

7.  Chronic Myelomonocytic Leukemia Presenting With Polyserositis and Seropositivity for Rheumatoid Arthritis.

Authors:  Anthony Kunnumpurath; Sai Prasad Desikan; Charles McClain; Raman Desikan
Journal:  J Investig Med High Impact Case Rep       Date:  2020 Jan-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.